Linaclotide Delayed Release Beads Enteric Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delayed release formulations of linaclotide face challenges due to its chemical instability, particularly moisture-induced degradation, making it difficult to achieve stable and targeted delivery to the lower gastrointestinal tract, which is essential for effective treatment of gastrointestinal disorders like irritable bowel syndrome and constipation.
Innovation Solution
Development of stable, solid, oral dosage forms of linaclotide with delayed release profiles, utilizing enteric-coated beads or tablets coated with pH-sensitive polymers like Eudragit and HPMC, along with stabilizing agents such as sterically hindered amines and cations, to ensure linaclotide release primarily in the lower GI tract, minimizing degradation and maintaining efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate release formulation is used, then linaclotide is released throughout the GI tract, but excess fluid secretion occurs in upper GI tract causing adverse effects
Solution Approach 1:
The formulation is segmented into enteric-coated beads that release linaclotide at specific GI tract locations. The enteric coating acts as a spatial separator, preventing drug release in the upper GI tract while enabling targeted release in the lower GI tract, thus resolving the contradiction between therapeutic efficacy and adverse fluid secretion.
Solution Approach 2:
The patent applies local quality by creating different release properties at different GI tract locations. The enteric coating provides acid resistance in the upper GI tract (pH < 5.6) while allowing drug release in the lower GI tract (pH > 5.6), ensuring the drug acts locally where needed without causing systemic adverse effects.
2Reliability
If delayed release formulation with enteric coating is used, then targeted release in lower GI tract is achieved, but linaclotide stability during storage and transit is compromised due to moisture sensitivity
Solution Approach 1:
The patent uses composite materials by combining linaclotide with hydrophobic polymers (ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate) and stabilizing agents (sterically hindered amines like octylamine, cations like calcium carbonate) within the bead matrix. This composite structure provides both moisture protection during storage and controlled release properties in the GI tract.
Solution Approach 2:
The enteric coating acts as a flexible protective shell that is impermeable to moisture during storage and transit, yet becomes permeable at the target site. The coating provides a barrier that protects the moisture-sensitive linaclotide until pH-triggered dissolution occurs in the lower GI tract, resolving the contradiction between stability and targeted delivery.
3Quantity of substance
If higher dose of linaclotide is administered to overcome degradation, then more drug reaches lower GI tract, but adverse events like diarrhea increase due to upper GI activation
Solution Approach 1:
The patent extracts the harmful effect of upper GI tract activation by using enteric coating to prevent drug release in that region. By taking out the upper GI tract from the drug release equation, the formulation allows higher doses to be administered without proportionally increasing adverse events, as the drug is selectively delivered only to the lower GI tract.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable delayed release compositions effectively target the lower GI tract, reducing adverse events like diarrhea while maintaining or improving the therapeutic efficacy for treating gastrointestinal disorders by ensuring consistent and prolonged release of linaclotide, thus addressing the instability and delivery issues of previous formulations.
Implementation Method 1
coated with pH-sensitive polymers like Eudragit and HPMC, to ensure linaclotide release primarily in the lower GI tract
Implementation Method 2
stabilizing agents such as sterically hindered amines and cations, to ensure linaclotide release primarily in the lower GI tract, minimizing degradation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.